Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Evommune, Inc.NYSE: EVMN
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Accumulated OCI vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 Accumulated OCI of $0 is the 5th highest of the 10 companies compared; the peer median is -$2K.
- Accumulated OCI amounts to 0.0% of total assets for EVMN, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.48M | -47.3% | — | 0.2% | |
| Mar 2026 | $802K | -13.1% | +6.9% | 0.3% | |
CLYMClimb Bio, Inc. | Mar 2026 | $157K | -45.1% | — | 0.1% |
| Mar 2026 | $43K | +113.4% | — | 0.0% | |
EVMNEvommune, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | -$2K | -125.0% | +10.1% | 0.0% | |
| Mar 2026 | -$11K | -178.6% | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$18K | — | — | 0.0% |
| Sep 2026 | -$6.66M | -10.1% | — | 0.6% | |
FTREFortrea Holdings Inc. | Jun 2026 | -$196.5M | -26.3% | — | 7.2% |
| Peer median (excluding EVMN) | -$2K | -35.7% | +8.5% | 0.1% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.